Literature DB >> 15164093

Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis.

J Schedel1, C A Seemayer, T Pap, M Neidhart, S Kuchen, B A Michel, R E Gay, U Müller-Ladner, S Gay, W Zacharias.   

Abstract

The present study was undertaken to examine whether ribozymes cleaving specifically cathepsin L (CL) mRNA are able to decrease the synthesis of CL protease in rheumatoid arthritis synovial fibroblasts (RA-SF) and thereby reduce the invasiveness into cartilage both in vitro and in the SCID mouse coimplantation model of RA. Two different ribozymes that cleave CL mRNA specifically at positions 533 (RzCL533) and 790 (RzCL790) were generated. Using retroviral gene transfer, RA-SF were transduced with the ribozyme constructs or the empty vector. To examine the effect of the ribozymes on the mRNA level, quantitative analysis for CL mRNA was performed using real-time PCR. For evaluation on the protein level, ELISA using specific anti-CL antibodies was performed. In addition, transduced RA-SF were examined in vitro in a three-dimensional destruction assay evaluating their ability to degrade extracellular matrix produced by human chondrocytes. Matrix destruction was monitored by the release of soluble glycosaminoglycans (sGAG). Using the in vivo SCID mouse coimplantation model of RA, RzCL533-transduced RA-SF and control cells were coimplanted with human cartilage for 60 days. After being killed, invasion of RA-SF into the cartilage was evaluated by using a semiquantitative score. Transduction of RA-SF with RzCL533 and RzCL790 ribozymes decreased significantly the expression of CL mRNA to 44% (range 25-62%) and 20% (range 1-43%), respectively, when compared to mock-transduced cells. The protein concentration of CL in the cell culture supernatants of transduced RA-SF was decreased from 16.0 ng/ml in the mock constructs to 4.1 and 8.2 ng/ml (mean), respectively. Using the in vitro cartilage destruction assay, the release of sGAG decreased to 46 and 60%, respectively, after 14 days when compared to mock-transduced cells. In the SCID mouse coimplantation model of RA, RzCL533-transduced RA-SF revealed a significant lower cartilage invasion when compared to mock and untransduced cells. Using retroviral gene transfer, ribozymes cleaving CL mRNA inhibit specifically the synthesis of this matrix-degrading enzyme and reduce cartilage destruction in in vitro and in vivo models. Our study therefore suggests that ribozymes targeting CL could be a novel and efficient tool to inhibit joint destruction in RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164093     DOI: 10.1038/sj.gt.3302265

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

Review 1.  Gene targeting: roadmap to future therapies.

Authors:  Lars C Huber; Thomas Pap; Ulf Müller-Ladner; Renate E Gay; Steffen Gay
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 2.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

3.  Cigarette smoke condensate increases cathepsin-mediated invasiveness of oral carcinoma cells.

Authors:  Nagathihalli S Nagaraj; Wolfgang Zacharias
Journal:  Toxicol Lett       Date:  2007-03-01       Impact factor: 4.372

Review 4.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

5.  Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.

Authors:  Michael C Myers; Parag P Shah; Mary Pat Beavers; Andrew D Napper; Scott L Diamond; Amos B Smith; Donna M Huryn
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

6.  Gene expression profiles of peripheral blood mononuclear cells in primary biliary cirrhosis.

Authors:  Lei Zhang; Danxu Ma; Xi Li; Chuiwen Deng; Qun Shi; Xin You; Xiaomei Leng; Mengtao Li; Fulin Tang; Fengchun Zhang; Yongzhe Li
Journal:  Clin Exp Med       Date:  2014-11       Impact factor: 3.984

7.  A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.

Authors:  Parag P Shah; Tianhua Wang; Rachel L Kaletsky; Michael C Myers; Jeremy E Purvis; Huiyan Jing; Donna M Huryn; Doron C Greenbaum; Amos B Smith; Paul Bates; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-05-13       Impact factor: 4.436

8.  Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment.

Authors:  Uta Schurigt; Rene Eilenstein; Mieczyslaw Gajda; Carola Leipner; Lisa Sevenich; Thomas Reinheckel; Christoph Peters; Bernd Wiederanders; Rolf Bräuer
Journal:  Inflamm Res       Date:  2012-06-07       Impact factor: 4.575

9.  Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts.

Authors:  Elena Neumann; Birgit Riepl; Anette Knedla; Stephanie Lefèvre; Ingo H Tarner; Joachim Grifka; Jurgen Steinmeyer; Jurgen Schölmerich; Steffen Gay; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-05-12       Impact factor: 5.156

10.  Over-expression of extracellular superoxide dismutase in mouse synovial tissue attenuates the inflammatory arthritis.

Authors:  Dong Hoon Yu; Jun Koo Yi; Hyung Soo Yuh; Seo jin Park; Hei Jung Kim; Ki Beom Bae; Young Rae Ji; Na Ri Kim; Si Jun Park; Do Hyung Kim; Sung Hyun Kim; Myoung Ok Kim; Jeong Woong Lee; Zae Young Ryoo
Journal:  Exp Mol Med       Date:  2012-09-30       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.